Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review - Takeaways - MDSpire

Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review

  • By

  • Hyunmin Ji

  • Jeong-Ju Yoo

  • Sang Gyune Kim

  • Young Seok Kim

  • June 17, 2026

  • 0 min

Share

  • 1

    Lenvatinib, a multi-target tyrosine kinase inhibitor, is used for advanced hepatocellular carcinoma but may increase hemorrhagic risks.

  • 2

    A 54-year-old man developed spontaneous lobar intracerebral hemorrhage after seven months of lenvatinib therapy, despite no traditional risk factors.

  • 3

    Brain MRI revealed a large lobar ICH without evidence of metastatic tumor or vascular abnormalities, complicating diagnosis.

  • 4

    The patient's mild thrombocytopenia was insufficient to explain the hemorrhage, indicating a potential link to lenvatinib.

  • 5

    This case highlights the need for vigilance in monitoring neurological symptoms in patients undergoing lenvatinib treatment.

Original Source(s)

Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review

  • by Hyunmin Ji, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim

  • June 17, 2026

Related Content

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice

The study points to a possible off-the-shelf cell therapy for solid tumors

  • June 16, 2026

  • 3 min
Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

  • June 15, 2026

  • 2 min